Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxcyte Inc PCVX

Healthcare Biotechnology
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation... see more

Recent & Breaking News (NDAQ:PCVX)

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire April 17, 2023

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

GlobeNewswire April 17, 2023

Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies

GlobeNewswire April 16, 2023

Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

GlobeNewswire March 30, 2023

Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire February 27, 2023

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

GlobeNewswire February 21, 2023

Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

GlobeNewswire February 16, 2023

Vaxcyte to Present at the SVB Securities Global Biopharma Conference

GlobeNewswire February 7, 2023

Vaxcyte's VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

GlobeNewswire January 5, 2023

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

GlobeNewswire December 20, 2022

Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 7, 2022

Vaxcyte to Present at Upcoming Investor Conferences

GlobeNewswire November 3, 2022

Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire October 28, 2022

Vaxcyte Announces Pricing of $600 Million Public Offering

GlobeNewswire October 26, 2022

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire October 24, 2022

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

GlobeNewswire October 24, 2022

Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults

GlobeNewswire October 23, 2022

Vaxcyte Expands Executive Leadership Team with Key Appointments

GlobeNewswire October 11, 2022

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

GlobeNewswire September 6, 2022

Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 8, 2022